Melanoma - Research Protocols

MELANOMA

EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
PI:  Marvin J. Feldman




For more information about ongoing clinical trials at the Alvin & Lois Lapidus Cancer Institute, please contact the oncology research team at 410-601-6120